Further pre-clinical developmental efforts such as the cloning and expression of these mimotopes using a lactococcal vector for potential oral administration, T-cell specific activation assays, delayed-type hypersensitivity reactions, dosage optimization, toxoids-fused mimotopes for improved immunogenicity, and various pharmacological studies are currently underway as we continue to develop 164-D mimotope into a potential cancer vaccine against G13D KRAS(+) malignancies. This evidence concerns the gene KRAS and cancer.